Literature DB >> 11754351

Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety.

Tom Wolfe1, Adrian Bot, Anna Hughes, Ursula Möhrle, Evelyn Rodrigo, Juan Carlos Jaume, Steinunn Baekkeskov, Matthias von Herrath.   

Abstract

Administration of autoantigens through DNA immunizations or via the oral route can prevent progression of islet destruction and lower the incidence of type 1 diabetes in animal models. This beneficial effect is mediated by autoreactive regulatory CD4 lymphocytes, and it is known that their induction depends on the precise dose and route of antigen administration. However, it is not clear which endogenous factors determine when such immunizations lead to activation of regulatory versus aggressive autoreactive lymphocytes and how a deleterious outcome can be avoided. Here we describe novel observations made in an animal model for virally induced type 1 diabetes, showing that the endogenous expression levels of the islet antigens and glutamic acid decarboxylase determine whether immunization with these antigens is beneficial or detrimental. Lower expression levels in beta-cells support immune regulation resulting in induction of autoreactive, regulatory cells characterized by increased IL-4 production (Th2-like), whereas higher levels favor Th1-like autoaggressive responses characterized by augmented IFN-gamma generation. Co-immunization with an IL-4-expressing plasmid reduces the risk of augmenting autoaggression and in this way increases the safety margin of this immune-based therapy. Our findings will be of importance for designing safe antigen-specific interventions for human type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754351     DOI: 10.1002/1521-4141(200201)32:1<113::AID-IMMU113>3.0.CO;2-C

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice.

Authors:  A Gauvrit; M Debailleul; A-T Vu; P Sai; J-M Bach
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 2.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

3.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

Review 4.  Manipulating the type 1 vs type 2 balance in type 1 diabetes.

Authors:  Urs Christen; Matthias G von Herrath
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 5.  Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform.

Authors:  Peter Gottlieb; Paul J Utz; William Robinson; Lawrence Steinman
Journal:  Clin Immunol       Date:  2013-09-01       Impact factor: 3.969

6.  AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice.

Authors:  Khaja K Rehman; Massimo Trucco; Zhong Wang; Xiao Xiao; Paul D Robbins
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

7.  Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice.

Authors:  Kevin S Goudy; Bo Wang; Roland Tisch
Journal:  Clin Immunol       Date:  2008-10       Impact factor: 3.969

Review 8.  Antigen-specific therapeutic approaches for autoimmunity.

Authors:  Pau Serra; Pere Santamaria
Journal:  Nat Biotechnol       Date:  2019-02-25       Impact factor: 68.164

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.